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The primary comorbidity and cause of mortality in type 2 diabetes is cardiovascular 
disease. The structural and the functional cardiac remodeling observed in patients with 
type 2 diabetes has been shown to be driven by a plethora of mechanisms including 
mitochondrial dysfunction and oxidative stress. Monoamine oxidase (MAO), an enzyme 
located on the outer mitochondrial membrane, catabolizes catecholamines to produce 
two reactive byproducts upon substrate deamination: catechol-aldehyde and H2O2. We 
hypothesized that within environments of decreased redox buffering capacity like type 2 
diabetes, these byproducts of MAO metabolism disrupt mitochondrial respiration and 
further drive redox imbalance. Furthermore, we hypothesized that the antioxidant and 
aldehyde scavenging capacity of carnosine could mitigate the reactivity of MAO-derived 
byproducts. A comprehensive analysis of catecholamine metabolism was performed in 
atrial myocardium from individuals with and without type 2 diabetes. MAO-A and-B 
maximal activity and expression were significantly increased within myocardium from 
individuals with diabetes and correlated with BMI. MAO-dependent metabolism of 
norepinephrine decreased ATP production within myocardium from individuals with type 
 
 
2 diabetes. In addition, decreased aldehyde dehydrogenase and increased basal levels 
of catechol-protein adducts were observed within this metabolic group. Metabolomic 
analysis of atrial tissue from individuals with diabetes showed decreased catecholamine 
levels in the myocardium, supporting an increased flux through MAOs. As a proof of 
concept of our second hypothesis we showed that carnosine was able to sequester 
DOPAL, the dopamine-derived catecholaldehyde. Carnosine also attenuated DOPAL-
dependent decrease in state 3 respiration in permeabilized fibers isolated from atria. 
Furthermore, the production of catechol-modified proteins was mitigated by carnosine in 
a concentration dependent manner. In conclusion, these findings illustrate a pathogenic 
mechanism for MAO within type 2 diabetes, and suggest that MAO-derived byproducts, 
especially catecholaldehydes, contribute to redox imbalance and altered mitochondrial 
bioenergetics observed in myocardium of individuals with type 2 diabetes. In addition, this 
translational study provides a mechanistic framework for the study of carnosine or related 
aldehyde scavengers as therapeutic approach for the prevention of cardiac dysfunction 
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PROGRESSION OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES 
 
Type 2 diabetes mellitus is a progressive and complex metabolic disease 
characterized by hyperglycemia and insulin resistance (1-3). For individuals with type 2 
diabetes the primary comorbidity and cause of mortality is cardiovascular disease (4). 
Sustained hyperglycemia and insulin resistance contribute to micro- and macrovascular 
complications within the heart, including coronary artery disease, myocardial infarction 
and arrhythmias (5). While each disease develops independently, they often converge 
at the inevitable endpoint of heart failure (HF), the risk of which is even greater in 
individuals with type 2 diabetes (6-9).  
Alterations in cardiac function and structural remodeling, most notably left 
ventricular (LV) hypertrophy and diastolic dysfunction, are associated with the 
progression of type 2 diabetes (10-13). The broader LV remodeling is a direct reflection 
of cellular stress within the myocardium. Within the myocardium are cardiomyocytes 
which orchestrate synchronous myocardial contraction and relaxation. Adult 
cardiomyocytes are non-proliferative which results in cellular remodeling in areas of 
myocardial injury including cardiomyocyte hypertrophy and myocardial fibrosis (14).  
Numerous molecular mechanisms and cellular pathways contribute to myocardial 





MECHANISMS CONTRIBUTING TO CARDIAC ALTERATIONS IN TYPE 2 
DIABETES 
 
Mitochondrial bioenergetics  
 In order to continuously support contractile functions, a high rate of ATP 
production occurs within the myocardium. Fatty acids are the primary substrate for ATP 
production and approximately 95% of the ATP in the heart is made via oxidative 
phosphorylation (OxPHOS) (16, 17). Through OxPHOS, ATP is made through an 
intricate system of redox reactions performed by complexes of the electron transport 
system (ETS) (18). The oxidation of nicotinamide adenine dinucleotide (NADH) and 
flavin adenine dinucleotide (FADH2) supplies the system with electrons which are 
passed from donors to acceptors until reaching molecular oxygen. Simultaneously, 
protons are translocated into the inter membrane space creating potential energy in the 
form of a proton motive force. Protons flow down their concentration gradient into the 
matrix through ATP synthase and the energy produced through the dissipation of the 
gradient produces ATP (19). The high rate of ATP production by OxPHOS is based 
upon its efficiency in coupling electron flow via redox reactions to ATP production. 
Therefore, disruptions in OxPHOS coupling can decrease production of ATP and 
consequentially disrupting contractile functions.  
Inefficiencies in cardiac OxPHOS have been observed in models of type 2 
diabetes including decreased activity of ETS complexes and decreased 
phosphocreatine/ATP ratios, a proxy of mitochondrial ATP production, which suggest a 
mismatch in ATP supply and demand (20-23). In individuals with type 2 diabetes, the 
reduction in ATP production was associated with decreased contractile function (20, 22, 




2 diabetes without apparent LV dysfunction and these findings imply that dysregulation 
of mitochondrial metabolism precedes and contributes to structural changes (22, 24).  
 
Oxidative stress  
Oxidative stress is considered a major causal factor of cardiomyocyte damage 
within the diabetic condition. In addition to its role in OxPHOS, the ETS is a large source 
of mitochondrial reactive oxygen species (ROS) production, most notably superoxide 
(25). As an oxidative precursor, superoxide potentiates the production of other ROS 
including H2O2, hydroxyl radicals and reactive nitrogen species (25). The toxicity of ROS 
are conferred through their ability to oxidize macromolecules including unsaturated 
lipids, proteins/enzymes, and mitochondrial DNA (26, 27). Within the mitochondria, 
electrophilic radicals, most notably ROS, oxidize polyunsaturated lipids within the 
membranes resulting in the formation of lipid peroxidation products including 4-hydroxy-
nonenal (4HNE) and malondialdehyde (MDA) (28). As reactive aldehydes, 4HNE and 
MDA can drive further oxidation of macromolecules including the formation of aldehyde-
protein adducts (28, 29).   
 Evidence of ROS-induced cellular damage is prominent in myocardium of 
individuals with type 2 diabetes as observed by increased protein oxidation, 
mitochondrial and cellular DNA damage, 4HNE and MDA-aldehyde adducts and 
cardiomyocyte apoptosis (30-34). In addition, detoxification of ROS and reactive 
aldehydes are compromised in the diabetic condition. Glutathione, located in the 
mitochondria and cytosol, is a primary antioxidant defense system which converts H2O2 
into water. Glutathione is maintained in the reduced state (GSH) and oxidized (GSSG) 




redox state (35). Furthermore, superoxide dismutase (SOD) and catalase (CAT) are 
antioxidants responsible for the detoxification of superoxide and H2O2. Decreased GSH: 
GSSG ratio, SOD, and CAT were detected in myocardium of individuals with type 2 
diabetes which indicate an underlying oxidative environment associated with diabetes 




Monoamine oxidase (MAO) is an enzyme located on the outer mitochondrial 
membrane and metabolizes intracellular catecholamines (norepinephrine, dopamine) 
and biogenic amines (serotonin, tyramine). Two isoforms of MAO, MAO-A and MAO-B 
are ubiquitously expressed throughout the human body and share approximately 70% 
homology (38). Each isoform exhibits preference for substrates and inhibitors; MAO-A 
shows greater specificity for 5-HT (serotonin) and is inhibited by clorgyline whereas 
MAO-B shows greater specificity for beta-phenylethylamine (β-PEA) and is inhibited by 
selegiline (deprenyl) (39, 40). Both forms metabolize tyramine (TYR), dopamine (DA), 
and norepinephrine (NE) equally (41, 42).  
Three byproducts are produced through the metabolism of catecholamines by 
MAO: ammonia, H2O2, and an aldehyde (termed ‘catecholaldehyde’), with the latter two 
exhibiting greater reactivity (41). The two most researched catecholaldehydes are 3,4-
dihydroxyphenylacetaldehyde (DOPAL) and 3,4-dihydrophenylglycolaldehyde 
(DOPEGAL) which are formed from the metabolism of DA and NE, respectively (43). 
DOPAL and DOPEGAL are quickly metabolized by separate aldehyde detoxification 




dihydroxyphenylacetic acid (DOPAC)) by aldehyde dehydrogenases (ALDH) and 
DOPEGAL is converted to an alcohol (3, 4-dihydroxyphenylethanol (DOPET)) by aldose 
reductase/aldehyde reductase (AR) (44, 45). DOPAL and DOPEGAL can be 
metabolized by the alternate aldehyde detoxification pathway, but to a significantly 
lesser extent (45). Since the active sites of MAO-A and MAO-B face the inner and outer 
mitochondrial membranes, respectively, byproducts formed by MAO deamination enter 
both cytosolic and inner mitochondrial domains (46, 47).  
 
THE PATHOGENIC ROLE OF MONOAMINE OXIDASE WITHIN CARDIOVASCULAR 
DISEASE 
 
MAO has been studied extensively since the 1970’s and was identified as playing 
a key role in the neuronal cell death associated with Parkinson’s disease. However, few 
studies have investigated the pathogenic role of MAO within cardiovascular disease 
(48-51). In animal models of cardiac pressure overload, MAO-A and -B activities were 
shown to contribute to increased LV hypertrophy, diastolic dysfunction and 
cardiomyocyte death all of which are pathognomonic of HF (52-54). Additionally, similar 
observations were made in an animal model of type 1 diabetes wherein MAO-A 
inhibition attenuated diastolic dysfunction and oxidative stress within the myocardium 
(55). Although the mechanisms by which MAO contribute to cardiac injury within 
diabetes and HF are unclear, the observed oxidative damage and cellular remodeling 






REACTIVITY OF MAO-DERIVED H2O2 AND CATECHOLALDEHYDES 
 
In vitro studies have shown MAO-derived H2O2 to be reactive, based upon its 
conversion to hydroxyl radicals, leading to the depletion of reduced glutathione, 
induction of oxidative damage to mitochondrial DNA, and formation of lipid peroxidation 
of mitochondrial membranes (56-60). Unlike H2O2, which requires a reductant to be 
converted to hydroxyl radicals, catecholaldehydes are inherently reactive due to the two 
functional groups within its structure, the catechol and aldehyde. Both functional groups 
are strong electrophiles and can bind to amino acid residues to form catecholaldehyde-
protein adducts (61). DOPAL covalently modifies cysteine, lysine, and methionine 
residues of enzymes leading to decreased or inhibited catalytic activity (61-65). 
Furthermore, within neuronal cells, DOPAL and DOPEGAL generated free hydroxyl 
radicals which induced apoptosis through the opening of the mitochondrial permeability 
transition pore (66-68).  
Within the ‘healthy’ cell, MAO-derived byproducts are quickly metabolized to 
stable products, yet as the cellular redox balance shifts towards an oxidative state (i.e. 
disease), the detoxification of catecholaldehydes becomes diminished. DOPAL, 4HNE, 
and MDA are substrates of and detoxified by aldehyde dehydrogenase (ALDH), yet, at 
concentrations which exceed physiological concentrations (10µM),  4HNE and MDA 
inhibited the activity of ALDH resulting in increased DOPAL concentration (69-71). 
ALDH activity requires the cofactor NAD+ which is synthesized from complex I of the 
ETS. In cell models, the inhibition of complex I by rotenone led to an increase in 
concentration of DOPAL due to compromised NAD+ production (72, 73). Interestingly, 




4HNE were observed in myocardium of type 2 diabetic models suggesting disrupted 
catecholaldehyde detoxification (31, 74, 75).   
 
CARNOSINE AS A REACTIVE ALDEHYDE SCAVENGER 
 
While the inhibition of MAO is an obvious target to prevent myocardial production 
of catecholaldehydes the use of MAO inhibitors by individuals with diabetes is 
contraindicated as MAO inhibition may sustain adrenergic signaling and precipitate a 
hypertensive crisis. Several groups have demonstrated that the antioxidants N-acetyl 
cysteine, glutathione and ascorbic acid were efficacious in preventing DOPAL-protein 
adduct formation in vitro, however these compounds were ineffective in reversing or 
detoxifying proteins modified by DOPAL, limiting their benefits to prophylactic use (63, 
72, 76).  
Carnosine is an endogenously synthesized dipeptide (β-alanine and L-histidine) 
found in millimolar concentrations in the heart (77, 78). Carnosine is synthesized in 
skeletal muscle, brain and heart by carnosine synthase and metabolized in plasma by 
carnosinase (CN1) (79-82).  The cellular activity of carnosine is multi-faceted as it 
exhibits pH buffering, metal chelating, antioxidant and aldehyde quenching abilities, that 
sugges its suitability for reducing reactivity of biogenic aldehydes (77, 83). The aldehyde 
quenching ability of carnosine is conferred by the histidine’s imidazole group and the 
lysine’s carboxyl group (84-87). Within proteins, the imidazole and carboxyl groups are 
nucleophiles and common sites of adduction by electrophilic aldehydes. The aldehydes 
covalently bind to the two nucleophilic groups of carnosine which serve as ‘decoy’ 




aldehydes (85). In vitro studies have shown carnosine to covalently bind to 4HNE and 
MDA to form aldehyde-carnosine adducts (86, 88). Carnosine can also bind to 
aldehydes previously attached to proteins to create a protein-aldehyde-carnosine 
adduct or ‘carnosylated’ conjugate (89, 90). Aldose reductase (AR), the enzyme which 
metabolizes DOPEGAL, is also thought to be responsible for reducing and enhancing 
the water solubility of carnosine-aldehyde products (91, 92).  
Carnosine improves global oxidative stress associated with obesity/insulin 
resistance observed by enhanced detoxification of carnosine-4HNE adducts detected in 
serum, urine, and liver. (93-96). Endogenous levels of carnosine in diabetic and 
hypertensive rats were significantly decreased compared to controls, which indicate the 
presence and activity of carnosine may be compromised within cardiometabolic disease 
(97, 98). Although the ability of carnosine to detoxify MAO-derived byproducts has not 
been investigated yet, these findings provide strong evidence of carnosine’s ability to 




As observed in animal models, MAO contributes to the cardiac dysfunction 
associated with diabetes and HF, however the mitochondrial and cellular implications of 
MAO-derived byproducts within diabetes remains unknown. Therefore, the work 
presented in this dissertation was driven by the central hypothesis that within 
myocardium from individuals with type 2 diabetes, MAO byproducts contribute to 
dysfunction in mitochondrial bioenergetics and redox imbalance. The following aims 




and the consequences of MAO-derived byproducts on mitochondrial energy production 
within patients with type 2 diabetes and our second aim was to investigate 
catecholaldehyde detoxification pathways and carnosine as a potential therapeutic to 
scavenge catecholaldehydes. The second chapter of this dissertation explores MAO 
activity within human myocardium and elucidates the impact of MAO-derived 
byproducts on OxPHOS. The chapter also examines catechol-protein adducts and 
catecholaldehyde detoxification pathways in individuals with and without type 2 
diabetes. Chapter three focuses on non-enzymatic detoxification of catecholaldehydes 
and the ability of carnosine to scavenge catecholaldehydes. The fourth chapter 
integrates the major findings from each chapter and proposes that the reactive 
byproducts produced by MAO, especially catecholaldehydes, contribute to myocardial 















CHAPTER 2:  
ENHANCED CATECHOLAMINE FLUX THROUGH MONOAMINE OXIDASE CAUSES 
MITOCHONDRIAL TOXICITY IN HUMAN HEART WITH DIABETES 
 
From Nelson MA, Efird JT, Kew KA, Katunga LA, Beatty CN, Akhter SA, Alwair H, 




Following the initial reports of the Framingham Study decades ago, persistent 
efforts were made to uncover pathophysiological mechanisms underlying cardiac 
complications associated with diabetes (99). Myocardial tissue remodeling and electro-
mechanical dysfunction underlie most of these complications, and the role of 
cardiomyocyte bioenergetics and redox imbalance in these processes has recently 
come to the forefront. Mitochondria are at the nexus of cardiomyocyte energetics and 
redox balance, which is why disruptions in energy production and mitochondrial sources 
of reactive oxygen species (ROS) have been explored as pathogenic factors 
contributing to cardiometabolic disease (100, 101). Established sources of mitochondrial 
ROS include NADPH oxidase and sites within the electron transport system (ETS), 
while lipid peroxidation of the mitochondrial membrane is a source of reactive aldehydes 
(e.g. 4-hydroxy-nonenal (4HNE), malondialdehyde (MDA)) (102-104). More recently, 
monoamine oxidase (MAO) has emerged as a significant source of both H2O2 and 




Two isoforms, MAO-A and MAO-B are located on the outer membrane of the 
mitochondrion and metabolize primary amines (e.g. norepinephrine (NE), dopamine 
(DA)) to produce ammonia, H2O2 and the highly reactive and toxic catecholaldehydes: 
3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) and 3,4-dihydroxyphenylacetaldehyde 
(DOPAL) (38, 43). Although short-lived, the toxicity of catecholaldehydes stems from 
their ability to form covalent aldehyde protein adducts (63, 106, 107). 
Catecholaldehydes are primarily detoxified via oxidation (aldehyde dehydrogenase, 
ALDH) or reduction (aldose reductase, AR, AKR1B1) (43, 108, 109).  
A pathogenic role for MAO was described in animal models of heart failure, 
ischemia, and more recently, diabetic cardiomyopathy (52, 55, 57, 110). While these 
studies laid the groundwork for establishing MAO as a pathological factor, the 
translational significance of these studies and the pathophysiologic mechanisms by 
which MAO may be acting, remain uncertain. Therefore, we performed a 
comprehensive biochemical analysis of catecholamine metabolism from atrial 
myocardium of age-matched patients with or without type 2 diabetes, with a particular 
emphasis placed on MAO expression and enzymatic activity. Given that MAO-derived 
catecholamine metabolites (i.e., catecholaldehydes) are highly reactive, we tested the 
hypothesis that within myocardium from patients with diabetes, increased MAO activity 
contributes to mitochondrial dysfunction by disrupting oxidative phosphorylation 
(OxPHOS).  
RESEARCH DESIGN AND METHODS 
 
Patient enrollment, blood and atrial tissue collection. All experiments involving 




School of Medicine at East Carolina University and the University of Iowa. Patients 
undergoing non-emergent elective coronary artery bypass graft (CABG) or CABG/valve 
surgery were enrolled between January 2011 and July 2018. Inclusion criteria included 
patients between the age of 50-70 without a previous history of cardiac surgery or 
arrhythmia. A fasted blood draw was performed before the initiation of anesthetics. Prior 
to placement on cardiopulmonary bypass, a portion of myocardium was biopsied in 
each patient after establishing a purse-string suture around the right atrial appendage. 
Myocardial tissue was dissected, rinsed in ice-cold PBS and used immediately for 
mitochondrial experiments. A separate portion of myocardium was snap frozen and 
maintained at -80°C for biochemical and metabolomics analysis.  
 
Quantitative analysis of MAO-A and –B enzyme content in myocardium. Standards 
and samples were added to immunolon-coated 96-well assay plates and incubated 
overnight at 4°C. The plates were washed with PBS+0.05% Tween-20 and blocked with 
5% BSA at 37°C. Samples were incubated with primary antibodies for MAO-A or –B 
(Abcam, Cambridge, MA) followed by incubation with horseradish peroxidase-
conjugated secondary antibody. Amplex Red (Thermo Fisher Scientific, Waltham, MA) 
was added and the fluorescence was measured at Excitation/Emission 567/590nm.  
For MAO-A and -B western blots, 20µg of sample protein lysate was loaded onto a 10% 
acrylamide gel and subject to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). The proteins were transferred to a PVDF membrane and 
blocked with 5% BSA in TBS-Tween. The membranes were incubated with primary 




secondary antibodies and imaged using Odyssey imaging system (Li-Cor Bioscience, 
Lincoln, NE).  
 
MAO enzymatic activity in myocardial tissue.  MAO activity was determined by 
measuring H2O2 production in the presence of Amplex Red. Each assay was measured 
in 1.5mLs using Amplex Red (10 µM), horseradish peroxidase (1U/mL), superoxide 
dismutase (25U/mL), and 15µL of myocardial lysate. Enzymatic activities were 
normalized to the concentration of isozyme obtained from the ELISA and reported as 
nmol/min/mg enzyme. 
 
Measurement of DA and NE using LC-MS. After homogenization, samples were 
centrifuged at 14,000g for 30 min. The supernatant was placed under nitrogen flow, 
maintained at 50°C, and evaporated to dryness.  The residue was resuspended in 1:1 
methanol: H2O. Standards of catecholamines (10ng/mL to 1500ng/mL) were prepared 
in 1:1 H2O: methanol and maintained at -20°C prior to use. Quantitative analysis of 
catecholamines were performed using an Exion LC/AB SCIEX 3200 triple quadropole 
mass spectrometer (AB SCIEX, Framingham, MA).  LC was performed using a Hypersil 
Gold aQ (3x50mm, 1.9µm) column (Thermo). The following gradient solvents were 
utilized: mobile phase A: 95:5 water:acetonitrile with 0.1% formic acid and B: 100% 
methanol with a flow rate of 0.3 mL/min. A 15 min total run time was used with a linear 
gradient from 97% B over 8 min was held for 1 min, decreased to 0% B for 1 min and 
equilibrated for 5 min. A 10µL injection volume was used from each sample. Parameters 




1. Concentrations of DA and NE were based upon the standard curve and normalized to 
tissue weight. 
 
Preparation of permeabilized muscle fibers (Pmfbs). Previous methods published 
from our lab were used to prepare permeabilized muscle fibers (Pmfbs) from atrial 
myocardium  (31).  After excision of myocardium from the atrial sample, ~300mg 
myocardium was placed in ice-cold Buffer X (7.23 mM K2EGTA, 2.77mM CaK2EGTA, 
20mM imidazole, 0.5mM DTT, 20mM taurine, 5.7mM ATP, 14.3mM phosphocreatine, 
6.56mM MgCl2-6H2O, 50mM KMES, pH 7.1) followed by a 30 min incubation with 
3µg/mL of collagenase type I (Worthington, Lakewood, NJ) at 4°C. Using fine tip 
tweezers, muscle fiber bundles were separated along the longitudinal axis and 
permeabilized in 10µg/mL saponin for 30 min. The fibers were then incubated in the 
respiratory buffer containing blebbistatin until used for respiratory experiments (<1 
hour). Oxygen flux was quantified using Oroboros DatLab software. To prevent 
extramitochondrial production of ATP, P1, P5-di(adenosine-5’) pentaphosphate (AP5a), 
an adenylate kinase inhibitor, was added. Experiments were performed using Buffer Z-
lite (10mM K-MES, 30mM KCl, 10mM KH2PO4, 5mM MgCl2-6H2O, 0.5mg/mL BSA, 
20mM creatine), 1mM EGTA, 200µM NADP+, 4mM glucose, 1.7U/mL of glucose-6-
phosphate, and 3.4U/mL of hexokinase. The recordings were normalized for 10 min 
followed by the addition of 50µM palmitoyl-L-carnitine and 2mM malate. After 3 min, 
500µM ADP was added to drive maximal respiration. After each experiment myofibers 
were collected and stored at -20°C in a freezing buffer (Buffer X, glycerol, protease 





Mitochondrial analysis in permeabilized human cardiac myofibers. Simultaneous 
and real-time ATP/O2 measurements were measured using a customized system which 
connected a spectrofluorometer (HORIBA Scientific, Edison, NJ) to an Oroboros O2K 
Oxygraph (Oroboros, Innsbruck, Austria) via lightguides. The glucose-6-phosphate 
dehydrogenase/hexokinase coupled enzyme system links the conversion of glucose, via 
mitochondrial ATP production, to the reduction of NADP+ to NADPH which is 
autofluorescent at Ex/Em 345/460. The rate of ATP production was calculated based on 
a standard curve of fluorescence corresponding to known ATP concentrations. Oxygen 
flux was quantified using Oroboros DatLab software. Experimental conditions are as 
outlined in the Figure legends. 
 
Normalization of mitochondrial content in permeabilized muscle fibers. To 
estimate mitochondrial content within Pmfbs, citrate synthase activity was measured 
based upon published methods (111). Fibers were removed from freezing buffer, 
homogenized 1:20 (w/v) in Tris- buffer (100mM Tris-base, 2mM EDTA pH 7.5) and 
centrifuged for 10 min at 10,000g at 4°C. Homogenates were diluted 1:10 with Tris-
buffer and added onto a clear polysterene 96 well plate. A reaction cocktail including 
5,5’-Dithiobis(2-nitrobenzoic acid), acetyl-CoA, and oxaloacetate was added to each 
well and absorbance was measured at 412nm every min for 10 min. Citrate synthase 
activity was calculated using the extinction coefficient of 13.6 L mol-1cm-1 and the results 





Detection of catecholaldehyde-modified proteins Nitroblue tetrazolium (NBT) is a 
redox-cycling dye which binds to catechol-protein adducts within a nitrocellulose 
membrane and stains the proteins blue, allowing the visualization of catechol-modified 
proteins (70, 112). Myocardial lysate alone, or after having been incubated with 
catecholamines -/+ MAO inhibitors, was subjected to SDS-PAGE. The gel, filter paper, 
and nitrocellulose membrane were incubated in Bjerrum Schaefer-Nielsen transfer 
buffer (48mM Tris-Base, 39mM glycine, 20% methanol) and transferred at 10V for 70 
min. The membrane was incubated in NBT solution (0.24mM NBT in 2M potassium 
glycine buffer) in the dark for 40 min followed by imaging using a ChemiDoc Imaging 
System (Bio-Rad, Hercules, CA).  
 
ALDH2 activity and protein expression. Aldehyde dehydrogenase 2 (ALDH2) is the 
mitochondrial isoform of aldehyde dehydrogenase (ALDH) and is responsible for 
metabolizing catecholaldehydes into weak acids. ALDH2 activity was measured based 
upon previous methods and determined by monitoring the ALDH2 conversion of NAD+ 
to NADH reflected by an increase in absorbance at 450nm (113). Assays were 
performed using 50mM sodium pyrophosphate buffer (pH 8.0), 200µg of cardiac protein 
lysate, 2.5mM NAD+, and 2µM rotenone. The reaction was initiated with the addition of 
10mM acetaldehyde and absorbance was recorded every 30s for 15 min. The detection 
of ALDH2 within myocardial lysates was performed using Western Blot techniques 





Metabolomic profiling of myocardial samples. An Eksigent 425 microLC/SCIEX 
5600+ time-of-flight mass spectrometer (AB SCIEX) was used to measure metabolites 
within myocardial samples. Samples were prepared the same as the NE and DA LC-MS 
preparation. A Halo C18 0.5 x 50 mm 2.7 µm column used for separation of the 
metabolites with the following solvent compositions:  mobile phase A:  95:5 
water:acetonitrile with 0.1% formic acid and B: acetonitrile with 0.1% formic acid.  A 
linear gradient was utilized with a flow rate of 10 µL/min where the gradient started with 
10% B for 2 min, increased to 90% B for 15 min, held for 5 min, dropped to 10% B over 
2 min and equilibrated for 10 min for a total run time of 30 min. Injection volume for 
samples was 5 µL. Data was acquired for MS and MS/MS analysis using independent 
data acquisition for the top 20 ions in positive ionization mode. The scan range for MS 
was 80-1250 Da. Principal component analysis (PCA) and t-tests were conducted using 
MarkerView 1.3.1. Statistically significant masses were tentatively identified using the 
Human Metabolome Database (hmbd.ca) and confirmed with MS-MS or a standard. 
Pathway analysis was then conducted via Metaboanalyst (http://www.metaboanalyst.ca) 
on database identified peaks (114, 115). 
 
Statistical Analysis. In the human clinical data analysis, categorical variables are 
presented as frequency and percentage and continuous variables were presented as 
mean ± standard deviation. Fisher exact and Chi (χ2) procedures were used to compute 
statistical significance of group comparisons for categorical variables. The Deuchler-
Wilcoxon test was used for continuous variables. For the multivariable analysis, 




model with relative risk (RR) of diabetes as the measure of association. Missing values 
for all clinical and biochemical variables (<5%) were imputed using the iterative 
expectation-maximization (EM) algorithm (30, 36). P-value in multivariable analysis was 
computed using Friedman’s nonparametric test for central tendency while adjusting for 
age, sex and race.  Ptrend was computed using likelihood ratio trend test, adjusting for 
age and sex. SAS Version 9.4 (Cary, NC) was used for all analyses of human 
biochemical and clinical variables. For MAO kinetic measurements, best-fit curves were 
implemented using nonlinear regression analysis and rates of MAO activity were 
compared between metabolic groups at each titration timepoint.  
The LC-MS, ELISA, ALDH2 activity and immunoblot densitometry were analyzed 
using unpaired Students t-tests to compare values between metabolic groups. Multiple 
paired Student’s t-test were used to compare differences in treatment groups of 
mitochondrial respiration experiments. Metabolomic data was analyzed using PCA 
followed by Student’s t-test to compare peak values between metabolic groups. Data 
was presented as mean ± SEM and values of p<0.05 were considered statistically 
significant. All analysis was performed using GraphPad Prism 8 (GraphPad Software, 




MAO expression and activity is up-regulated in right atria of patients with 
diabetes. For this study, samples of right atrial myocardium were analyzed from 96 
patients, 51 with type 2 diabetes and 45 with normal glycemic control. As detailed in 




significant differences in pre-operative medications were observed between groups, 
with exception of the angiotensin-converting enzyme inhibitors/angiotensin II receptor 
blockers and the antihyperglycemics, as would be expected (Table 1).  
Since MAO metabolizes intracellular catecholamines, we first measured 
catecholamine levels within the myocardium. NE was found to be the predominant 
catecholamine within the samples, and patients without diabetes showed significantly 
greater concentrations of DA (p<0.001) and NE (p=0.012) in their myocardium, as 
compared to patients with diabetes (Figure 1A). It was recently shown that MAO 
expression is increased in heart with insulin resistance/diabetes (55, 116). Therefore, 
we measured myocardial MAO enzyme content and activity in myocardial extracts. 
Results from the quantitative ELISA revealed that the predominant MAO isoform within 
atrial myocardium was MAO-A. In univariable analysis, both MAO isoforms were 
significantly increased within myocardium from patients with diabetes (p<0.05) at total 
enzyme level (Figure 1B and 1C). After adjusting for age, sex, and race, multivariable 
analysis revealed that only MAO-A was significantly higher in patients with diabetes 
(p=0.024) (Table 2).  
To further characterize MAO, kinetic assays were performed using clorgyline 
(MAO-A inhibitor) and selegiline (MAO-B inhibitor) to distinguish isoform specific 
activity. Assay specificity for each isozyme is shown with these inhibitors in 
Supplemental Figure 1.  MAO kinetics differed between metabolic groups and the effect 
was variable across the monoamine substrates tested. The observed Vmax for both 
MAO-A and –B isoforms were higher in patients with type 2 diabetes when DA was 




was used (Figure 1D). Multivariable analysis confirmed that MAO-A activity supported 
by DA and NE was significantly increased within myocardium from patients with 
diabetes (Supplemental Table 2.1 and 2.2). With β-phenylethylamine (βPEA), the 
observed Vmax of MAO-A and –B appeared to be lower in patients with diabetes (Figure 
1D). No significant effect was observed between metabolic groups when 5-HT or TYR 
were used as substrates. Taken together, these results indicate that MAO expression is 
increased, while enzymatic activities are altered in a monoamine substrate-specific 
manner in diabetes.  
Irrespective of metabolic status, over 70% of the patients within the cohort were 
determined to be either overweight or obese (BMI 25-33.3). Therefore, we sought to 
determine if there was an association between MAO and obesity and determined that 
BMI is associated with dopamine-supported maximal activity of both isoforms MAO-A 
(R2=0.23, p=0.001) and MAO-B (R2=0.21, p=0.002) (Figure 2A and B). An association 
was also found between glycated hemoglobin (HbA1c) levels and MAO-A (R2=0.12, 






Table 1. Patient characteristics and preoperative medications (n=96). 
* p-value computed using Student’s t-test 


































Figure 1. Cardiac MAO protein expression and enzymatic activity in human 
myocardium  
LC-MS analysis of dopamine and norepinephrine concentrations in human atrial 
myocardium (A) from patients with type 2 diabetes and non-diabetes (n=15/metabolic 
group). MAO-A and -B concentrations measured using MAO isoform specific antibodies 
via (B) ELISA (n=45-55/metabolic group) and (C) western blot, α-tubulin was used as 
the loading control (n=6/metabolic group). Kinetic traces of MAO activity (D) using 5 
biogenic substrates: norepinephrine, dopamine, serotonin, beta-phenylethylamine and 
tyramine. MAO activity was measured by monitoring the increase in fluorescence of 
resorufin at Ex/Em: 571/585. MAO-A activity is shown on the top panel and MAO-B 
activity is on the bottom panel (n=20/metabolic group).  Data are represented as ±SEM. 
*p<0.05, **p<0.005 compared with non-diabetes. 5-HT, serotonin. βPEA, beta-



















†   p-value computed using Friedman’s Nonparametric test for central tendency,  
adjusting for age, sex and race. 













































Figure 2.  Maximal MAO activity and association with metabolic parameters 
Shown are pairwise correlations between BMI and observed Vmax of (A) MAO-A and 
(B) MAO-B. In (C) and (D) are pairwise correlations between HbA1c and observed 
Vmax of MAO-A and MAO-B, respectively. For this analysis MAO activity was 























MAO activity disrupts mitochondrial OxPHOS in myocardium patients with 
diabetes. Metabolism of TYR and DA by MAO caused suppression of mitochondrial 
respiration in isolated rat brain mitochondria, but whether catecholamine metabolism by 
MAO disrupts mitochondrial bioenergetics within the heart is not known (117, 118). To 
address this question, we measured mitochondrial OxPHOS (ATP production/O2 
consumption) using permeabilized myofibers (Pmfbs) prepared from fresh samples of 
atrial myocardium. In Pmfbs isolated from patients without type 2 diabetes, incubation 
with NE did not significantly alter ATP production or O2 consumption (Figure 3A and B). 
Metabolism of NE by MAO significantly decreased ATP production (p<0.05) in Pmfbs 
from patients with type 2 diabetes while O2 consumption was not significantly affected 
(Figure 3A and B). This attenuation in ATP production corresponded to a decrease in 
ATP/O ratio (Figure 3C). This effect was confirmed to be driven by MAO metabolism of 









Figure 3: MAO-derived byproducts disrupt OxPHOS. Simultaneous (A) ATP 
production, (B) O2 consumption and (C) ATP/O ratio were measured in permeabilized 
fibers prepared from atrial myocardium treated with: no MAO substrate or inhibitors, 
75µM NE, MAO inhibitors, or MAO inhibitors + 75µM NE. n=10/metabolic group with 4 






Metabolism of catecholamines by MAO generates catechol-protein adducts in 
extracts of atrial myocardium. DOPAL and DOPEGAL are quickly metabolized by 
ALDH2 and AR into acetic acid (dihydroxyphenylacetic acid, DOPAC) and alcohol 
(dihydroxyphenylglycol, DHPG) respectively, which are their primary routes of 
metabolism (Figure 4A). However, when these detoxification pathways are 
overwhelmed, catecholaldehydes have been shown to form catechol-protein adducts 
(43, 49, 63, 76). To our knowledge, there has been no previous study examining 
formation of catecholaldehydes or catechol-modified protein adducts in myocardial 
tissue. Therefore, we first measured unbound DOPAL and DOPAC in plasma and 
myocardial extracts using quantitative MS/MS approach. In plasma, free DOPAL level 
were increased in patients with type 2 diabetes, while DOPAC levels were found to be 
similar between the metabolic groups (Supplemental Figure 2). Within myocardium, 
DOPAL and DOPAC concentrations were below the detectable limit of the instruments 
used.  
This was not surprising, however, because owing to their high reactivity, free 
catecholaldehydes are unlikely to be present in myocardium. Therefore, we refined a 
technique using nitroblue tetrazolium (NBT), to determine if myocardial tissue contains 
catechol-modified protein adducts. NBT is a dye that selectively reacts with the catechol 
moiety on proteins to form a stable blue conjugate on nitrocellulose membrane (Figure 
4B). Myocardial extracts all contain catechol-modified protein adducts at baseline, with 
substantially greater levels within myocardium from patients with diabetes (Figure 4C). 
Extracts exposed to NE, and to a lesser extent, DA, revealed an increase in catechol-




dependent upon MAO activity, which strongly suggests that MAO-derived 
catecholaldehydes are responsible for this modification (Figure 4E).   
Within the mitochondria, aldehydes formed from lipid peroxidation (4HNE, MDA) 
are metabolized by ALDH2, the same enzyme which primarily metabolizes DOPAL, and 
to a lesser extent, DOPEGAL (30, 70, 106). Studies have shown that 4HNE and 
DOPAL, at high concentrations, can allosterically inhibit ALDH2 activity, thereby 
creating a ‘bottleneck’ for aldehyde detoxification (69, 71). Furthermore, a recent study 
from our lab revealed that myocardium from patients with type 2 diabetes contain 
greater amounts of 4HNE compared to patients without diabetes, suggesting basal 
aldehyde stress within the cardiac mitochondrial microenvironment of these patients 
(30). In animal models of diabetes, the attenuation of ALDH2 activity lead to an increase 
in aldehyde load and contributed to left ventricular dysfunction (119, 120). Since ALDH2 
is involved in catecholaldehyde metabolism, ALDH2 content and activity was measured 
in atrial myocardium. Interestingly, while there were no differences in ALDH2 enzyme 
content between the metabolic groups (Figure 4F and G), ALDH2 activity was 

























Figure 4: Detection and metabolism of catecholaldehydes in myocardium Pathway 
of catecholamine metabolism into catecholaldehydes (by MAO) and then into acetic 
acid (DOPAC) or alcohol (DHPG) by ALDH2 or AR, respectively (A). If metabolism by 
ALDH2 or AR is compromised, catecholaldehydes can form carbonyl adducts with 
proteins. Shown in (B) is a representative image of catechol-protein adduct detection by 
NBT staining. In the presence of catechol-modified proteins  NBT stains proteins blue 
on nitrocellulose membrane. Representative NBT stains of cardiac lysate untreated(C),  
after overnight incubation with DA (25µM) or NE (75µM) (D), and after overnight 
incubation with MAO inhibitors +/- NE (75µM) (E).  Western blot analysis (F) and 
densitometric analysis (G) of ALDH2 in myocardium. COX IV was used as a loading 
control to calculate relative density. n=7/metabolic group. ALDH2 activity (H) measured 
by monitoring the increase in absorbance of NADH at 450nm in myocardial samples. 
n=14/metabolic group. *p<0.05. All data are shown as mean±SEM. ALDH2, aldehyde 
dehydrogenase 2. AR, aldose reductase. COX IV, complex IV. DA, dopamine. DHPG, 
dihydroxyphenylglycol. DOPAC, dihydroxyphenylacetic acid. MAOi, Monoamine oxidase 





Metabolomic profiling shows pathways of catecholamine synthesis and 
metabolism are altered in heart with diabetes. To examine whether the changes in 
MAO and ALDH2 corresponded to alterations in total catecholamine flux within the 
myocardium, global metabolomics analysis was performed on atrial tissue from a subset 
of patients in each group. LC/MS peak profiling revealed 592 unique metabolite features 
across all samples. Principle component analysis (PCA) results showed defined 
clustering by diabetes status (Fig. 5A). After analysis of the 592 metabolites, 110 
features were found to be statistically different between metabolic groups (Fig. 5B). 
Based upon m/z and retention times, the metabolites were queried and identified using 
the human metabolomic database (HMDB) and compiled into MetaboAnalyst™ for 
pathway analysis. Results showed that the three most significant pathways that were 
significantly different were phenylalanine, tyrosine and tryptophan metabolism pathways 
(Fig. 5C). The tyrosine metabolism pathway is broad and responsible for the synthesis 
and metabolism of TYR, DA and NE and includes associated MAO and ALDH 
byproducts. Based upon further MS/MS analysis, we identified and confirmed 5 
metabolites within the tyrosine/catecholamine pathway that were significantly different in 
the myocardial tissue from the diabetes patients (Supplemental Table 3).  
Tyrosine can either be converted to TYR or L-DOPA, the product of tyrosine 
hydroxylase. TYR is then converted to its associated catecholaldehyde, 
hydroxyphenylacetaldehyde (HPAL), by MAO. Samples from patients with diabetes had 
much lower levels of hydroxyphenylacetic acid (HPAA) (p<0.05), the metabolite of 
HPAL produced by ALDH, which is consistent with reduced ALDH activity in these 




and NE (p<0.05), were also decreased with diabetes. While no differences were 
observed within DA metabolism, dihydroxyphenylglycol (DHPG), the alcohol metabolite 
of DOPEGAL, was substantially decreased in myocardial tissue from diabetes patients 












Figure 5: Metabolomics pathway analysis of human atrial myocardium. LC-MS 
analysis of metabolic profiles was performed using cardiac lysate. (A) is a 
representative PCA scores plot showing clusters based on metabolic status. (B) After 
alignment and data extraction 592 metabolite features were detected of which 110 were 
found to be statistically significant between metabolic groups (p≤0.05). (C) 
Metaboanalyst pathway analysis revealed that five of the metabolites were involved 
within the tyrosine metabolism pathway (D). The five metabolites shown in the 
abbreviated tyrosine pathway were confirmed by comparison of the observed mass 
fragmentation patterns and retention times to those published in the Human 
Metabolome Database. Peak areas of the identified metabolites are compared and 
shown in D. All data are shown as mean±SEM. *p<0.05, **p<0.005 compared with non-
diabetes. DA, dopamine. DHPG, dihydroxyphenylglycol DOPAC, dihydroxyphenylacetic 
acid. DOPAL, dihydroxyphenylacetaldehyde. DOPEGAL, 
dihydroxyphenylglycolaldehyde.NE, norepinephrine. HPAA, hydroxphenylacetic acid. 













Figure 6: Schematic of MAO-derived byproducts within myocardium from patients 
with type 2 diabetes. MAO expression and activity are increased in myocardium of 
patients with type 2 diabetes, suggesting increased flux of catecholamines through 
MAO. In myocardium, MAO-derived byproducts form catechol-modified protein adducts 
(post-translational modifications) and decrease ATP production (energy disruption). In 
diabetes patients, the compromised ALDH2 activity would exacerbate these toxicities by 
creating a ‘detoxification bottleneck’). Long term toxicities and carbonyl stress due to 
MAO-derived byproducts could contribute to hypertrophy, fibrosis, and 
electrophysiological (EP) derangements, ultimately leading to electromechanical 
dysfunction in myocardium of diabetes patients. OCT3/ENMT = organic cation 
transporter-3/extraneuronal monoamine transporter; OMM = outer mitochondrial 
membrane; IMM = inner-mitochondrial membrane; ANT = adenine nucleotide 







This translational study provides direct evidence that there is a shift in catecholamine 
metabolic pathways within the myocardium of patients with type 2 diabetes. These 
findings suggest that within the myocardium, MAO activity increases, while ALDH 
activity decreases, and this has potentially profound impacts on redox balance and 
OxPHOS. Global metabolomics confirmed our biochemical analyses and suggest that 
increased MAO and decreased ALDH activities in myocardium from patients with 
diabetes are shunting catcholaldehydes (DOPAL and DOPEGAL) into alternative 
metabolic pathways, including formation of toxic protein adducts. 
Myocardium from patients with type 2 diabetes showed a substantial decrease in 
DA and NE concentration, compared to patients without diabetes.  We propose that the 
increased MAO-A and MAO-B expression and activity in these patients’ myocardium is 
responsible for this, as enhanced MAO activity would increase catecholamine flux. In a 
previous study of human myocardium, MAO expression was measured in atrial samples 
from patients who had heart failure (HF), or HF and diabetes combined, and no 
significant differences in MAO-A or -B expression were found between groups (121). 
However, while that group used real-time PCR and immunohistochemistry in fixed 
myocardial tissue, we performed immunoblot and ELISA analysis after validating the 
specificity of the MAO-A and -B antibodies using immunoblot with recombinant forms of 
each enzyme (Figure 1C). We then developed a quantitative ELISA method with these 
antibodies to determine isoform concentrations within a large cohort of patients and 
combined that with a comprehensive kinetic analysis of MAO-A and –B activity in the 




and MAO-B within patients with type 2 diabetes. A more interesting and potentially 
important finding in the MAO analysis is that both MAO-A and –B are catalytically 
altered in patients with diabetes. By normalizing the enzymatic activity to isoform 
content (via ELISA), we were able to determine that there are altered kinetics at the 
level of the enzyme itself. To our knowledge, this is the first time that the kinetics of 
these critical enzymes have been assessed in human myocardium. These findings also 
suggest that MAO catalytic activity is regulated at the post-translational level (e.g., 
phosphorylation, acetylation, carbonylation, etc), and that some post-translational 
modification of MAO belies the increased catalytic activity in the myocardium with 
diabetes. 
We found that metabolism of NE by MAO decreased mitochondrial ATP 
production in Pmfbs isolated from myocardium from patients with type 2 diabetes. This 
decrease in ATP production without a simultaneous change in oxygen consumption 
implies a decreased efficiency of the phosphorylation system (e.g., ATP-synthase, 
adenine nucleotide translocase, ANT), as opposed to a disruption in electron flux within 
the ETS. Since the effect of NE was mitigated by MAO inhibitors, it is most likely due to 
the reactivity of MAO-derived byproducts. Both H2O2 and aldehyde-dependent post-
translation modifications of the ATP synthase have been reported to affect ATP 
synthase efficiency (122-124). Future studies are warranted to elucidate mechanisms 
by which MAO-derived byproducts disrupt ATP production, and the extent to which 
these byproducts contribute to cardiomyocyte electromechanical dysfunction (Figure 6). 
While the potential pathogenic role of catecholaldehydes within the heart is not 




specifically in the pathogenesis of Parkinson’s disease. DOPAL induces protein 
aggregation, cell death, and inhibit tyrosine hydroxylase, the enzyme responsible for DA 
and NE biosynthesis (62, 107, 125, 126). Furthermore, these studies established that 
DOPAL and DOPEGAL induce mitochondrial-mediated cell death via opening of the 
permeability transition pore in dopaminergic cell models (66, 67, 117). Taking into 
consideration that subunits of the ATP-synthase comprise the permeability transition 
pore, it could be speculated that the decrease in ATP production observed in Pmfbs 
exposed to NE was due to transient opening of the PTP induced by catecholaldehydes. 
Our study also revealed ALDH2 activity to be compromised within myocardium 
from patients with type 2 diabetes. This mitochondrial-localized enzyme has a critical 
role in phase 2 detoxification and metabolism in oxidative tissues. Numerous studies of 
cardiac disease, including experimental models of diabetes, demonstrated the 
importance of ALDH2 in preserving myocardial structure and function (71, 127). 
Furthermore, therapeutic strategies that increase ALDH2 activity (Alda-1) or sequester 
aldehydes have shown promise in diabetes-associated cardiac complications (119, 
128). ALDH2 is among many enzymes responsible for metabolism of DOPAL and 
DOPEGAL. Although DOPAL or DOPEGAL within the myocardium were below the 
detectable limits of our MS instruments, we showed that catecholaldehyde protein 
adducts are present in human myocardium, and MAO contributes to their production. 
Most importantly, we found that catechol-modified protein adducts are more abundant in 
myocardial tissue from diabetes patients (Figure 4C). Taken together, these findings 
strongly suggest that an aldehyde ‘detoxification bottleneck’ may be present in the heart 




modification of proteins, thereby contributing to cardiotoxicity via carbonyl stress and 
redox imbalance in the myocardium of these patients. 
Among our patient cohort, there is variability in duration of time by which patients 
were treated with various medications for diabetes and/or cardiovascular disease. This 
was not accounted for in the present study as this data is not routinely captured in 
clinical records, thus we cannot exclude the possibility that duration of drug treatment 
(e.g. β-blockers, CCB’s, anti-hyperglycemics) may have somehow affected MAO 
isoform content and/or activity.  
Additionally, since the highest degree of sympathetic innervation in the heart is 
localized to the atrium, we cannot exclude the possibility that some MAO content/activity 
could be coming from post-ganglionic nerve terminals. Never-the-less, the fact that 
MAO is altered at both activity and enzyme kinetic level and that in Pmfbs, which are 
void of non-myocardial tissue, there is a significant effect of NE on mitochondrial ATP 
production in patients with diabetes, leads us to conclude that there is indeed a 
localized effect of MAO in myofibers that impacts mitochondrial OxPHOS.   
Finally, we were not able to directly quantify total amounts of catecholaldehydes 
(DOPAL, DOPEGAL) in myocardial extracts and only captured adducts formed on 
proteins via NBT staining. There are several reasons for this. First, catecholaldehydes 
in tissue are highly reactive and they spontaneously and rapidly react with solvent-
accessible Lys and Cys residues on proteins or are further metabolized via phase 2 
enzymes (48, 61). Additionally, these adducts are proving to be very challenging to 
measure with MS, due to their instability and reactivity. For example, DOPEGAL cannot 




is difficult to quantify. Despite these challenges we are confident that with continued 
refinement in our LC/MS and MS/MS methods we will have a highly sensitive and 
reproducible detection method in place very soon.    
This study provides direct evidence that catecholamine flux is significantly 
enhanced in human myocardium with diabetes, and that MAO-derived 
catecholaldehydes contribute to carbonyl stress and mitochondrial dysfunction in this 
tissue. While additional studies are necessary to completely understand the reactivity 
and cardiotoxicity of catecholaldehydes, these initial findings provide insight into a 
pathogenic mechanism by which MAO contributes to cardiac disease in diabetes (i.e. 
atrial fibrillation, cardiomyopathy). It is anticipated these results will inform future studies 
in experimental models concerning the role of MAO in cardiac diseases. Finally, our 
study suggests that targeting catecholamine metabolism and aldehyde detoxification in 





























Supplemental Table 1. Multiple reaction monitoring (MRM) parameters used for  











†     p-value computed using Friedman’s Nonparametric test for central tendency 
adjusting for age, sex and race. 
††  p-value computed using the likelihood ratio trend test adjusting for age, sex and race. 
 
Supplemental Table 2.1.  MAO isoform activity (DA as substrate) and Risk for Diabetes  




















Supplemental Figure 1: Validation of cardiac MAO-A and –B isozyme activity assay. 
Representative fluorescent traces of continuous H2O2 production from MAO isozyme-
specific activity in cardiac tissue lysate. Shown are experimental traces of total MAO 
activity supported by β-phenylethylamine (βPEA) (black solid line), MAO-B only (MAO-A 
is inhibited by Clorgyline (Clg), black dashed line), MAO-A only (MAO-B inhibited by 
Selegiline (Slg), gray dashed line), and background rate with both isozymes inhibited 











Supplemental Figure 2:  Concentrations of DOPAL and DOPAC within plasma. LC-
MS analysis of DOPAL and DOPAC concentrations within plasma from patients with and 





CHAPTER 3:  
BIOCHEMICAL CHARACTERIZATION OF THE CATECHOALDEHYDES 
REACTIVITY OF L-CARNOSINE AND ITS THERAPEUTIC POTENTIAL IN HUMAN 
MYOCARDIUM 
 
From Nelson MM, Builta ZJ, Monroe TB, Doorn JA, Anderson EJ. Biochemical 
characterization of the catecholaldehyde reactivity of L-carnosine and its therapeutic 




Catabolism of norepinephrine (NE) and dopamine (DA) by monoamine oxidase (MAO) 
constitutes the principal route of neurotransmitter metabolism in oxidative tissues. MAO 
metabolizes norepinephrine (NE) and dopamine (DA) to produce the catecholaldehydes 
3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) and 3,4-dihydroxyphenylacetaldehyde 
(DOPAL), respectively, and H2O2 (43). Products of oxidative stress inactivate the 
enzymes responsible for catecholaldehyde metabolism, amplifying their levels and 
toxicity (69-71). Both DOPEGAL and DOPAL have been demonstrated to be far more 
cytotoxic and reactive than the parent catecholamines (i.e., NE and DA) or any other 
known metabolites (129). The surprisingly high toxicity appears to stem from the 
reactivity of both catechol and aldehyde groups. Due to their electrophilic nature, 
catecholaldehydes form covalent and very stable adducts with protein amines (e.g., 
Lys) and other biological molecules, permanently modifying their structure and function, 





Carnosine is an endogenous histidyl dipeptide found in millimolar concentrations 
in skeletal muscle, heart and brain (83). The dipeptide has therapeutic effects, exhibiting 
pH buffering, metal chelating, and antioxidant properties. Numerous groups have 
documented the ability of carnosine to detoxify and form stable conjugates with oxidized 
sugar- and lipid-derived aldehydes, such as acrolein and 4-hydroxy-2-nonenal (4HNE), 
yet the ability of carnosine to conjugate catecholaldehydes has, to our knowledge, never 
been examined (84, 88, 131-134). Therefore, the aim of this study was to investigate if 
carnosine can attenuate reactivity and toxicity of catecholaldehydes through the 
formation of catecholaldehyde-carnosine conjugates. In addition, we sought to compare 
reactivity of carnosine with other endogenous nucleophiles and antioxidants, such as 
the tripeptide glutathione (GSH), and L-Cys, to determine if carnosine is a novel 
scavenger of catecholaldehydes. 
 
RESEARCH DESIGN AND METHODS 
 
Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise described. DOPAL was purchased from Cayman Chemicals or synthesized 
via the method of Fellman (135, 136). DOPEGAL was biosynthesized using 
commercially available MAO (137). 
 
Reactivity of Biogenic Aldehydes. DOPAL (100 µM) was incubated with 1 mM 
carnosine, 1 mM GSH or 1 mM L-Cys at 37 ºC in 50 mM sodium phosphate buffer, pH 




mixture and the reaction stopped by diluting 1:10 with 0.1% trifluoroacetic acid (TFA). 
Samples were stored at -20ºC in freezer or 4ºC in auto-sampler prior to analysis. The 
concentration of DOPAL was measured via a 1200 Series Agilent Capillary HPLC 
system with a photodiode array detector (202 and 280 nm). Separation was achieved 
using a Phenomenex C18 Luna column (1x150 mm) with flow rate of 50 µL/min and 
mobile phase of 0.1% TFA with 6% acetonitrile (isocratic). Dilution of the DOPAL-
conjugates in 0.1% TFA and incubation for up to 2hrs at 37ºC did not result in 
appreciable decomposition of the DOPAL-carnosine conjugate. 4HNE (100 µM) was 
incubated with 1 mM GSH or 1 mM carnosine and time-dependent change in 
concentration of 4HNE was measured spectrophotometrically at 224 nm. The reaction 
of 100 µM 4HNE with 1 mM carnosine was allowed to equilibrate for 20 min before 
recording the time-dependent change in [4HNE] to be used in the rate calculation. 
Given the rapid reaction of 100 µM 4HNE with 1 mM GSH, the time-point at 60 min (>7 
half-lives) was used as the blank for the reaction. Kinetics for the reaction of DOPAL 
and 4HNE with nucleophiles (e.g., carnosine, L-Cys) were pseudo-first order given the 
nucleophile (e.g., 1mM carnosine) was in 10-fold excess of the electrophile (e.g., 100 
µM DOPAL). During the course of the reaction, the change in [carnosine] would be very 
little compared to the change in [DOPAL].  
 
Human research participants, informed consent and collection of myocardial 
samples. This study was reviewed and approved by the Institutional Review Board of 
the Brody School of Medicine at East Carolina University. Enrolled in the study were 




and presented without a prior history of cardiovascular surgery or arrhythmias. Informed 
consent for participation in the study was obtained by a member of the research team 
who was not involved in data collection or analysis. Prior to the initiation of 
cardiopulmonary bypass, a purse-string suture was made around the portion of the right 
atrial appendage (RAA) for insertion of the venous cannula. A section of the RAA was 
then excised and immediately rinsed in phosphate buffered saline. Myocardium was 
dissected from the endocardial side of the right atrial biopsy and placed in ice-cold 
Buffer X (7.23mM K2EGTA, 2.77mM CaK2EGTA, 20mM Imidazole, 0.5mM DTT, 20mM 
Taurine, 5.7mM ATP, 14.3mM PCr, 6.56mM MgCl2-6H2O, 50mM K-MES) and 
immediately processed for mitochondrial measurements. A small portion was frozen in 
liquid N2 and maintained at -80°C for protein analysis. 
 
Preparation of permeabilized myofiber and mitochondrial O2 measurements 
Techniques used for permeabilization of human cardiac myocardium have been 
previously described (31, 36). Briefly, myocardial samples were placed in ice-cold Buffer 
X containing 3mg/mL Collagenase Type I on a rocker at 4°C for 30 minutes. Myocardial 
tissue was cleared of connective tissue and separated into fibers along the longitudinal 
axis followed by permeabilization in Buffer X containing 50µg/mL saponin for 30 minutes 
at 4°C. The fibers were washed in Buffer Z (in mM: 105 K-MES, 30 KCl, 1 EGTA, 10 
KH2PO4, 5 MgCl2-6H2O, 5mg/mL BSA) containing 20µM blebbistatin and placed on a 
rotator at 4°C until analysis (< 1 hour). Mitochondrial O2 consumption was measured 
using the O2K oxygraph system (Oroboros Instruments) at 30°C with continuous stirring. 




MES, 30 KCl, 1 EGTA, 10 KH2PO4, 5 MgCl2-6H2O, 0.5mg/mL BSA, 0.05 palmitoyl-L-
carnitine, 2 malate). State 3 respiration was initiated by the addition of 5 mM ADP and 
followed by titrations of DOPAL. A second fiber from each patient was pretreated with 
10 mM carnosine, 1 mM GSH or 1 mM L-Cys for 5 minutes prior to measuring state 3 
respiration.  
 
Analysis of catechol-modified proteins in isolated mitochondria. Mitochondria from 
myocardial atrial samples were isolated with methods adapted from previous studies 
(138). In brief, fresh myocardium was minced on ice for 4 minutes and underwent a 2-
minute trypsin digestion. To halt trypsin activity, trypsin inhibitor was added, and the 
mixture was placed in a 50mL conical tube and allowed to settle. The supernatant was 
removed, and the minced tissue was resuspended in mitochondrial isolation medium-
MIM (in mM: 300 sucrose, 10 Na-HEPES, 0.2 EDTA) and homogenized using a pre-
chilled Dounce homogenizer. The mixture was homogenized slowly with 10-12 strokes. 
The homogenate underwent differential centrifugation steps and the pellet of 
mitochondria were resuspended in MIM + BSA. Isolated mitochondria (50 µg) were 
incubated for 3 hours at 37°C with 75 µM NE and increasing concentrations of 
carnosine (1, 2.5, 5, 10, 25 mM). Mitochondrial proteins were subject to SDS-PAGE 
under reducing conditions followed by transfer to a nitrocellulose membrane. Nitro-blue 
tetrazolium (NBT) was used to detect catechol-modified protein adducts. NBT, a redox-
cycling dye, stains nitrocellulose blue in the presence of catechol functional group (61, 




glycine buffer and rinsed in distilled water. The membrane was imaged using a 
ChemiDoc Imaging System (Bio-rad).   
 
Statistical analysis. Data from this study are presented as means ± SEM or means ± 
SD, as noted. A student’s paired t-test was used to define differences between ADP-
stimulated respiration +/- carnosine within patient samples. Statistical significance was 
denoted at p<0.05 and statistical tests and linear regression were performed with 




Carnosine rapidly conjugates catecholaldehydes. Carnosine (1 mM) reacted with 
DOPAL (100 µM) and demonstrated pseudo-1st order kinetics with time-dependent loss 
of the catecholaldehyde in the presence of the dipeptide; however, much less reactivity 
was observed following incubation of carnosine (1 mM) with the lipid peroxidation 
product 4HNE (100 µM) (Figure 7A). The pseudo-1st order kinetics were anticipated 
given that [carnosine] >> [DOPAL], such that there was little change in [carnosine] with 
depletion of [DOPAL]. 
 In contrast, GSH (1 mM) rapidly scavenged 4HNE (100 µM) with a half-life of 
approximately 3 min for 4HNE but exhibited no reactivity towards DOPAL (100 µM) over 
the course of 120 min (Figure 7B). Like carnosine, L-Cys (1 mM) exhibited scavenging 
activity towards DOPAL (100 µM); however, the kinetics may not be pseudo-1st order 




progress to characterize the rapid kinetics of DOPEGAL reactivity towards carnosine 

























Figure 7. Comparison of DOPAL and 4HNE scavenging by antioxidants. The 
reaction of (a) 1 mM carnosine with 100 µM DOPAL or 100 µM 4HNE; (b) 1 mM GSH 
with 100 µM DOPAL or 100 µM 4HNE; (c) 100 µM DOPAL with 1 mM carnosine or 1 
mM L-Cys. Data are reported as mean ± SD (n=3, carnosine with DOPAL or 4HNE; L-
Cys with DOPAL), (n=4, GSH with 4HNE) or (n=2, GSH with DOPAL). Measured slopes 







Carnosine attenuates DOPAL toxicity in human cardiac mitochondria. 
Permeabilized myofibers exposed to titrations of DOPAL revealed a dose-dependent 
decrease in state 3 respiration, even exhibiting a significant drop with the initial addition 
of 1µM DOPAL (p<0.05). Simultaneous incubation of DOPAL with 10 mM carnosine 
significantly attenuated the decrease in respiration across all concentrations of DOPAL 
(Figure 8A), while incubation with GSH and L-Cys under similar conditions did not 











Figure 8. Carnosine attenuates DOPAL-dependent decrease in state 3 respiration. 
Effect of DOPAL titration on state 3 respiration in permeabilized myofibers isolated from 
human RAA, either alone or following a pre-incubation with carnosine (a), GSH (b) and 
L-cysteine (c). Respiration was supported by palmitoyl-carnitine & malate. Data are 
reported as mean ± SEM, *p<0.05 vs. DOPAL, Ψ p<0.05 vs vehicle, εp<0.05 L-






Carnosine mitigates catechol-protein modifications in human cardiac 
mitochondria. Isolated mitochondria incubated with NE showed a greater degree of 
NBT-staining (Figure 9) compared to the control lane (first lane), indicating increased 
presence of catechol-modified protein adducts. Pre-treatment of mitochondria with 
carnosine showed a concentration dependent decrease in catechol-modified adducts, 










Figure 9. Effect of carnosine on formation of catechol-modified adducts. 
Representative blot showing catechol-adduct protein modifications in isolated human 
cardiac mitochondria when incubated with norepinephrine (NE) and/or increasing 








The results from this study reveal, for the first time to our knowledge, the ability of 
carnosine to conjugate and sequester catecholaldehydes, the aldehyde byproduct of 
catecholamine deamination via MAO. Recent work has shown the rapid reactivity of 
DOPAL with protein amines, yielding stable adducts predicted to be a rearranged 
indole; however, the scavenging of DOPAL by carnosine was previously not known. 
Interestingly, GSH is not an effective scavenger of catecholaldehydes; however, GSH 
quickly reacts with the lipid peroxidation product 4HNE, while carnosine’s reactivity is 
much slower (76). Such findings demonstrate the novel ability of carnosine, but not 
GSH, to scavenge a unique class of biogenic aldehydes (i.e., catecholaldehydes), and 
suggest a biological role for carnosine in cytoprotection against endogenous 
electrophiles formed via neurotransmitter metabolism. In addition, while L-Cys and 
carnosine readily reacted with DOPAL, carnosine but not L-Cys appeared to generate a 
stable conjugate that was not reversible during the reaction time-frame. It is known that 
L-Cys conjugates with aldehydes (e.g., acetaldehyde) to form thiazolidine products, and 
previous reports have noted this reaction to be reversible (139). 
Our findings also indicate that carnosine mitigates catecholaldehyde-mediated 
disruptions in mitochondrial respiration, while GSH and L-Cys do not. Owing to the 
study design, our mitochondrial experiments cannot provide mechanistic insight as to 
how DOPAL decreases state 3 respiration in permeabilized myofibers, or perhaps more 
importantly, how carnosine is able to prevent the decrease in respiration. Never-the-
less, the decrease in respiration observed in the presence of DOPAL signifies an 




phosphorylation. Therefore, additional studies are necessary to investigate which 
specific enzymes within the electron transport and/or phosphorylation systems are 
modified by catecholaldehydes, and the broad effect of these modifications.  
Protein modification by catecholaldehyde adducts has been shown in work from 
our laboratory and others to cause toxicity in neuronal cell cultures and to contribute to 
the pathophysiology of neurological disease (49, 63, 130, 140, 141). Our finding that 
carnosine dose-dependently mitigates catecholaldehyde protein adduct formation 
following norepinephrine exposure in isolated human cardiac mitochondria indicates 
that 1) MAO content and activity is more than sufficient in human heart to generate 
catecholaldehydes when catecholamines are present; 2) there are numerous 
mitochondrial protein targets for these catecholaldehydes, as indicated by the large 
number of bands within each well of our NBT stain (Figure 9); and 3) carnosine is 
capable of blunting formation of catecholaldehyde protein adducts, even at 
physiologically relevant concentrations. In future studies, targeted proteomic- and 
metabolomic- based approaches will be necessary to elucidate the extent to which 
catecholaldehyde modifications alter cellular metabolism and mitochondrial energetics, 
and the potential for carnosine to mitigate these effects.  
In summary, our results highlight the capacity of carnosine to conjugate and 
scavenge catecholaldehydes, thus expanding the repertoire of carnosine reactivity 
beyond those formed by lipid- and sugar-derived aldehydes. Such findings indicate 
carnosine to be a unique scavenger for catecholaldehydes, a property not seen for 
GSH. There are many clinical implications for these findings. The carnosine-DOPAL 




in a variety of clinical applications in patients at risk for neurological and cardiovascular 
diseases. Furthermore, these findings illustrate the therapeutic potential of carnosine in 
pathological states where increased MAO activity and sympathetic tone (i.e., 
catecholamine overload), and compromised aldehyde detoxification are known to be 
involved (142-144).    























Collectively the findings from Chapter 2 and 3 support the central hypothesis that 
MAO-derived byproducts disrupt mitochondrial bioenergetics and contribute to redox 
imbalance within myocardium from individuals with type 2 diabetes. Using MAO gene 
deletion or irreversible inhibitors, several studies eloquently demonstrated that MAO 
activity is involved in the development of left ventricular diastolic dysfunction often 
observed in diabetes and HF (52, 53, 55). Yet, these studies were not able to detail the 
mechanisms by which MAO byproducts led to the observed cellular changes. The 
results of our studies strongly suggest that it is through the ability of MAO-byproducts, 
specifically catecholaldehydes, to form catechol-protein conjugates and disrupt 
OxPHOS contributing to myocardial damage in type 2 diabetes. These findings link the 
mechanisms by which MAO activity may contribute to structural and functional 
alterations of LV observed within type 2 diabetes. 
Within sympathetic cardiac nerve terminals, the release, uptake and storage of 
NE is maintained under tight regulation. Of the NE that is released at the presynaptic 
terminals, up to 90% is sequestered and returned by the norepinephrine transport (NET) 
while the remaining either enters circulation or is transported into myocardium and 
metabolized by MAO (145, 146). Several studies have shown increased sympathetic 
discharge and an inverse correlation between HbA1c and the expression of NET in 
myocardium from individuals with type 2 diabetes (147, 148). These results, in 




regulation of NE which may lead to greater myocardial uptake of NE within type 2 
diabetes.  
A significant finding from Chapter 2 is that MAO activity and expression are 
increased in individuals with type 2 diabetes. To our knowledge, this is the first report of 
alterations in cardiac MAO expression and activity within human subjects. Similar 
results have been reported using streptozotocin-induced diabetes that are more 
relevant to Type 1 Diabetes (55, 149-151).  Although the mechanisms by which MAO 
expression and activity were increased were not ascertained within this dissertation, 
several studies indicate increased sympathetic signaling subsequent to hypoxia as a 
potential mechanism. In animal models, hypoxic/ischemic conditions contributed to 
increased MAO-A expression and activity and the expression and activities of both MAO 
isoforms were increased in left and right ventricles in patients with HF secondary to 
ischemic heart disease (57, 152, 153). The upregulation of MAO, especially MAO-A, 
due to hypoxia has been established, yet how hypoxia leads to the upregulation is still 
being explored. Several groups speculated that it is due to increase NE release during 
ischemic periods, but other groups have shown MAO-inhibition prior to hypoxia 
prevented the upregulation of MAO (154-156).  The myocardium used in our studies 
was primarily from patients who suffered a myocardial infarction attributable to coronary 
artery disease, which indicates the myocardium was exposed to hypoxic conditions. 
Although hypoxic conditions due to coronary artery disease was a commonality 
between the metabolic groups, atherosclerotic lesions within coronary arteries in 
individuals with type 2 diabetes were more calcified, contained greater pro-inflammatory 




vascular smooth muscle death (157, 158). Furthermore, due to impairments in arterial 
vasodilation, abnormalities in coronary blood flow are observed in type 2 diabetes (159, 
160). Based on these findings, coronary artery disease within type 2 diabetes could be 
more severe leading to greater global hypoxia compared to patients without diabetes 
and accounting for increased in MAO expression/activity. In addition, the myocardium 
used in this study was dissected from the right atrial appendage. Infarcted and ischemic 
areas most commonly occur within the smaller branches of the coronary arteries 
surrounding the ventricles, yet atrial infarctions comprise 17% of all infarctions and can 
occur concomitantly with ventricular infarctions (161, 162). Moreover, 98% of atrial 
infarctions occur within the right atrial appendage (161, 163). As ventricular tissue is 
difficult to obtain, these findings support using right atrial myocardium as a 
representative of myocardial damage within type 2 diabetes.  
Results from Chapter 2 showed MAO-derived byproducts decreased ATP 
production in Pmfbs from individuals with type 2 diabetes. ATP synthase and adenine 
nucleotide translocase (ANT1) are two sites integral for ATP production via OxPHOS. 
ANT, located on the inner mitochondrial membrane, facilitates the exchange of ADP into 
the mitochondria and ATP into the cytosol therefore dictating the supply of ADP for 
OxPHOS (164).  Post-translational modifications of ANT, including phosphorylation of 
tyrosine residues within the substrate binding site, have shown to decrease ADP 
exchanging activity (165). This mechanism was unlikely attributable for our observations 
as the phosphorylation of these residues provokes the opening of the mitochondrial 
permeability transition pore that would disrupt oxygen consumption, an effect that was 




inhibited ANT activity in a concentration dependent manner through carbonyl 
modifications (166-168). Additionally, a recent study showed increased 4HNE protein 
adducts within myocardium from individuals with type 2 diabetes (30). Based upon the 
oxidative microenvironment observed in myocardium from individuals with type 2 
diabetes, it is possible that ANT was previously modified by PUFA-derived aldehydes 
and the additional reactivity of MAO-derived byproducts overwhelmed the activity of 
ANT, leading to decreased exchange of ADP/ATP, and thus decreased ATP production.  
The metabolomic results showed a propensity towards decreased 
catecholaldehyde detoxification in myocardium from individuals with type 2 diabetes. 
Although DOPAL and DOPEGAL could not be quantified due to the instrumentation 
used, catecholaldehyde production and reactivity are suggested to be higher in 
myocardium from individuals with type 2 diabetes based upon the observed increase in 
catechol-protein adduct formation and decreased ALDH2 activity. A primary focus of 
Chapter 2 was DOPAL and ALDH2 activity, however investigating DOPEGAL and AR 
activity are equally relevant. This is an apparent limitation of the study especially since 
NE is the primary catecholamine found within human heart (169, 170). Interestingly, AR 
activity has been suggested to be a pathogenic contributor to cardiac dysfunction 
observed in type 2 diabetes. The metabolism of reactive aldehydes to alcohols is a 
primary role of AR, yet in hyperglycemic conditions, it is involved with an aberrant 
pathway which metabolize excess glucose. Glycolysis is the central pathway for glucose 
metabolism, but after hexokinase becomes saturated, excess glucose enters the polyol 
pathway (171). In this pathway AR uses NADPH as a cofactor to convert glucose to 




glucose to sorbitol also increases the oxidation of NADPH. NADPH is required to 
reduce oxidized glutathione, a major antioxidant of the cell, yet due to the increased use 
of NADPH within the polyol pathway, the reduction of oxidized glutathione is attenuated 
leading to a redox imbalance (172). Within type 2 diabetes, AR activity is suggested to 
contribute to diastolic dysfunction, as studies which used AR inhibitors observed 
improvement in diastolic function and oxidative stress (173, 174). The dual ability of AR 
to detoxify reactive aldehydes (e.g. catecholaldehydes) while simultaneously driving 
redox imbalance by metabolizing glucose, reveals the complexities of oxidative stress 
and detoxification pathways within type 2 diabetes.  
The results from Chapter 2 highlighted deficient ALDH2 activity in individuals with 
type 2 diabetes which segued into investigating a potential compound to enhance 
catecholaldehyde detoxification. Within our study carnosine was able to irreversibly bind 
DOPAL in a pseudo-first order kinetics manner, prevented DOPAL-dependent decrease 
in oxygen consumption within Pmfbs, and mitigated the formation of mitochondrial 
catechol-protein adducts. In these studies, carnosine also extended greater scavenging 
reactivity with DOPAL compared to GSH or L-Cys and showed a different scavenging 
profile with DOPAL compared to 4HNE. While our study showed carnosine to extend 
minimal reactivity towards 4HNE in vitro, numerous studies have shown that carnosine 
binds to 4HNE to form carnosine-4HNE conjugates in vivo (87, 93, 175). Endogenous 
levels of carnosine are reduced in muscle of type 2 diabetes, proposed by increased 
CN1 activity, which suggests decreased availability of carnosine to scavenge aldehydes 
(97, 176, 177). As carnosine is readily metabolized in plasma by CN1, several groups 




reactivity. A recent study used oral carnosinol, a carnosine derivative which bypasses 
metabolism by CN1, that exhibited greater scavenging reactivity to 4HNE and acrolein 
compared to carnosine (94). These findings, in combination with findings from Chapter 
3, provide evidence of the therapeutic potential of carnosine or carnosine analogues to 
improve redox balance and mitochondrial respiration in type 2 diabetes by attenuating 




In order to better understand the pathogenic role of MAO within cardiac 
dysfunction observed in type 2 diabetes, future studies are warranted and will attempt to 
answer the following: 
1) In this study myocardium from individuals with type 2 diabetes exhibited 
increased MAO activity, even after normalizing to enzyme content, which 
suggests an enhanced catalytic activity within the diabetic condition. Based upon 
this finding, how is MAO catalytic activity altered in type 2 diabetes? 
Alterations in catalytic activity within disease states could be a result of pre- or 
post-translational modifications. Several studies have investigated 
polymorphisms of MAO-A within depression and correlated specific 
polymorphisms with decreased catalytic activity (178, 179). Based upon these 
studies, there does appear to be a causal link between disease state and 
genotype. These studies provide evidence to propose investigations of 
genotyping MAO-A within myocardium from individuals with and without type 2 




provide insight into potential substitutions within the substrate binding and active 
site. Additionally, to investigate post-translational modifications (PTM), chemical 
label and enrichment could be performed prior to proteomic analysis in order to 
detect most common PTM within specific amino acid residues. Further analysis 
of proteomic study would need to be performed to determine if specific 
modulations contribute to altered catalytic activity. 
 
2) Are MAO-derived byproducts synthesized in cardiomyocytes transmissible to and 
disrupt function of surrounding cells, including fibroblast, immune cells, endothelial 
cells, smooth muscle cells, adipocytes and other cardiomyocytes?  
The heart is comprised of multiple networks of cells of which cardiomyocytes only 
make up approximately 30%, therefore by understanding if MAO-derived byproducts 
are transmissible would provide insight into how localized myocardial damage 
caused by MAO-derived byproducts can affect the function of other cell types (14, 
180). A recent study showed that DOPAL and DOPAC produced and released by 
PC-12 cells were transported into co-cultured neuronal cells which then led to 
cytotoxic effects (181). A similar initial study could investigate the release and 
uptake of MAO and ALDH2 derived byproducts within cardiomyocytes and cardiac 
fibroblasts. Media could be removed from cardiomyocytes exposed to 
catecholamines and run through HPLC to detect MAO-derived byproducts. If 
byproducts are present, fibroblasts could be exposed to cardiomyocyte-extracted 
media and measured for cellular alterations including fibrosis progression (TGF-β, 




phenotype. These findings could help to underscore the greater impact of MAO 
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